FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155424478> ?p ?o ?g. }

• W2155424478 endingPage "805" @default.
• W2155424478 startingPage "2798" @default.
• W2155424478 abstract "SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor. In this Phase I dose escalation trial, a weekly dose schedule of SU5416 was tested whereby an initial 5-day loading dose was followed by weekly maintenance infusions. The start dose was 20 mg/m(2) for the loading dose followed by 65 mg/m(2) for the weekly infusions. Dose escalations occurred at 33% until a final dose of 65 mg/m(2) (loading dose) and 190 mg/m(2) (weekly infusion) was obtained. Twenty-two patients were treated at five dose levels; tumor types included gastrointestinal (8), breast (3), lung (4), sarcoma (2), and other (5). The most common serious drug-related toxicity was headache, often associated with nausea and vomiting. Grade 1 and 2 toxicities included headache, nausea, vomiting, asthenia, pain at the infusion site, phlebitis, change in voice, and fevers. Of 19 evaluable patients, 4 obtained clinical benefit as defined by tumor regression (1) or disease stabilization for at least 12 weeks (3). Pharmacokinetic data revealed that the weekly infusion schedule prevented the reported 50-60% induction in SU5416 clearance observed with either daily or twice weekly dosing. Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies. Our results suggest that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m(2)." @default.
• W2155424478 created "2016-06-24" @default.
• W2155424478 creator A5009941371 @default.
• W2155424478 creator A5014229357 @default.
• W2155424478 creator A5053118124 @default.
• W2155424478 creator A5077039831 @default.
• W2155424478 creator A5081069354 @default.
• W2155424478 creator A5089364285 @default.
• W2155424478 date "2002-09-01" @default.
• W2155424478 modified "2023-09-28" @default.
• W2155424478 title "Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies." @default.
• W2155424478 cites W103956845 @default.
• W2155424478 cites W139545237 @default.
• W2155424478 cites W1480371749 @default.
• W2155424478 cites W1513654399 @default.
• W2155424478 cites W1532019756 @default.
• W2155424478 cites W153934429 @default.
• W2155424478 cites W1559314541 @default.
• W2155424478 cites W1564365085 @default.
• W2155424478 cites W1586129343 @default.
• W2155424478 cites W1607187127 @default.
• W2155424478 cites W1756949381 @default.
• W2155424478 cites W1953884850 @default.
• W2155424478 cites W1976697969 @default.
• W2155424478 cites W1980334238 @default.
• W2155424478 cites W1983763042 @default.
• W2155424478 cites W1988211842 @default.
• W2155424478 cites W2003656890 @default.
• W2155424478 cites W2004239325 @default.
• W2155424478 cites W2014943535 @default.
• W2155424478 cites W2024753734 @default.
• W2155424478 cites W2029883816 @default.
• W2155424478 cites W2036142151 @default.
• W2155424478 cites W2037900330 @default.
• W2155424478 cites W2039410387 @default.
• W2155424478 cites W2040737235 @default.
• W2155424478 cites W2041212459 @default.
• W2155424478 cites W2042397185 @default.
• W2155424478 cites W2056669173 @default.
• W2155424478 cites W2069826874 @default.
• W2155424478 cites W2084844081 @default.
• W2155424478 cites W2084944550 @default.
• W2155424478 cites W2094627540 @default.
• W2155424478 cites W2097628587 @default.
• W2155424478 cites W2111266343 @default.
• W2155424478 cites W2117834514 @default.
• W2155424478 cites W2141046053 @default.
• W2155424478 cites W2150908379 @default.
• W2155424478 cites W2152505099 @default.
• W2155424478 cites W2166825418 @default.
• W2155424478 cites W2171275402 @default.
• W2155424478 cites W2309093863 @default.
• W2155424478 cites W2319962899 @default.
• W2155424478 cites W2320669141 @default.
• W2155424478 cites W2324677651 @default.
• W2155424478 cites W2409821120 @default.
• W2155424478 cites W3143314496 @default.
• W2155424478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12231519" @default.
• W2155424478 hasPublicationYear "2002" @default.
• W2155424478 type Work @default.
• W2155424478 sameAs 2155424478 @default.
• W2155424478 citedByCount "42" @default.
• W2155424478 countsByYear W21554244782012 @default.
• W2155424478 countsByYear W21554244782013 @default.
• W2155424478 countsByYear W21554244782014 @default.
• W2155424478 countsByYear W21554244782016 @default.
• W2155424478 countsByYear W21554244782018 @default.
• W2155424478 countsByYear W21554244782020 @default.
• W2155424478 crossrefType "journal-article" @default.
• W2155424478 hasAuthorship W2155424478A5009941371 @default.
• W2155424478 hasAuthorship W2155424478A5014229357 @default.
• W2155424478 hasAuthorship W2155424478A5053118124 @default.
• W2155424478 hasAuthorship W2155424478A5077039831 @default.
• W2155424478 hasAuthorship W2155424478A5081069354 @default.
• W2155424478 hasAuthorship W2155424478A5089364285 @default.
• W2155424478 hasConcept C112705442 @default.
• W2155424478 hasConcept C126322002 @default.
• W2155424478 hasConcept C2777288759 @default.
• W2155424478 hasConcept C2780580376 @default.
• W2155424478 hasConcept C2780852908 @default.
• W2155424478 hasConcept C29730261 @default.
• W2155424478 hasConcept C31760486 @default.
• W2155424478 hasConcept C35294091 @default.
• W2155424478 hasConcept C71924100 @default.
• W2155424478 hasConcept C90924648 @default.
• W2155424478 hasConcept C98274493 @default.
• W2155424478 hasConceptScore W2155424478C112705442 @default.
• W2155424478 hasConceptScore W2155424478C126322002 @default.
• W2155424478 hasConceptScore W2155424478C2777288759 @default.
• W2155424478 hasConceptScore W2155424478C2780580376 @default.
• W2155424478 hasConceptScore W2155424478C2780852908 @default.
• W2155424478 hasConceptScore W2155424478C29730261 @default.
• W2155424478 hasConceptScore W2155424478C31760486 @default.
• W2155424478 hasConceptScore W2155424478C35294091 @default.
• W2155424478 hasConceptScore W2155424478C71924100 @default.
• W2155424478 hasConceptScore W2155424478C90924648 @default.
• W2155424478 hasConceptScore W2155424478C98274493 @default.
• W2155424478 hasIssue "9" @default.

• next